Published in Clin Cancer Res on November 01, 2006
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res (2008) 2.01
Advances in quantitative UV-visible spectroscopy for clinical and pre-clinical application in cancer. Curr Opin Biotechnol (2009) 1.44
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer (2009) 1.44
Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer (2009) 1.29
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun (2014) 1.17
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res (2011) 1.10
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 1.08
Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer (2007) 1.07
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch (2010) 1.06
Gene expression and hypoxia in breast cancer. Genome Med (2011) 1.02
Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev (2008) 0.94
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer (2012) 0.93
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Res (2007) 0.93
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res (2011) 0.93
The bZIP transcription factor Rca1p is a central regulator of a novel CO₂ sensing pathway in yeast. PLoS Pathog (2012) 0.92
Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med (2008) 0.90
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer (2009) 0.87
Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem (2014) 0.86
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res (2011) 0.86
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. J Cancer Res Clin Oncol (2013) 0.85
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol (2016) 0.85
Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer (2008) 0.84
Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr Med Chem (2014) 0.82
Reduction of CAII Expression in Gastric Cancer: Correlation with Invasion and Metastasis. Chin J Cancer Res (2012) 0.80
The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women. PLoS One (2013) 0.78
Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One (2015) 0.78
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. Breast Cancer Res (2008) 0.77
Hypoxia-specific targets in cancer therapy: role of splice variants. BMC Med (2010) 0.77
The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression. BMC Cancer (2013) 0.76
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol (2014) 0.76
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Arch (2016) 0.75
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2005) 3.26
The landscape of recombination in African Americans. Nature (2011) 3.06
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 2.78
Fibulins: physiological and disease perspectives. EMBO Rep (2003) 2.56
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev (2009) 2.37
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol (2005) 2.26
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol (2007) 2.12
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res (2008) 2.01
Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol (2009) 1.99
Enhanced statistical tests for GWAS in admixed populations: assessment using African Americans from CARe and a Breast Cancer Consortium. PLoS Genet (2011) 1.94
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res (2006) 1.87
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Comparative analysis of breast cancer risk factors among African-American women and White women. Am J Epidemiol (2005) 1.81
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev (2007) 1.76
In vitro demonstration of the heavy-atom effect for photodynamic therapy. J Am Chem Soc (2004) 1.74
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg (2010) 1.68
Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev (2009) 1.67
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol (2010) 1.64
FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis (2010) 1.63
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle (2011) 1.60
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol (2005) 1.57
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res (2003) 1.56
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev Mol Diagn (2008) 1.48
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet (2011) 1.45
Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control (2007) 1.44
Intracellular and extracellular microRNAs in breast cancer. Clin Chem (2010) 1.44
Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res (2006) 1.43
Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites: a population-based case-control study. Carcinogenesis (2006) 1.42
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene (2005) 1.42
Survivin: a promising tumor biomarker. Cancer Lett (2007) 1.41
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem (2012) 1.41
p53 as a target for the treatment of cancer. Cancer Treat Rev (2014) 1.38
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat (2013) 1.38
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
miRNA dysregulation in breast cancer. Cancer Res (2013) 1.35
FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer (2009) 1.35
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol (2009) 1.34
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis (2007) 1.34
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res (2005) 1.34
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res (2008) 1.34
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem (2010) 1.32
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis (2013) 1.32
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer (2009) 1.30
Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat (2006) 1.30
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res (2003) 1.27
ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res (2007) 1.25
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol (2012) 1.24
The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur J Cancer (2009) 1.24
Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet (2013) 1.24
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer (2003) 1.23
BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res (2013) 1.22
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer (2006) 1.20
An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol (2010) 1.20
The role of S100 genes in breast cancer progression. Tumour Biol (2010) 1.19
Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc (2004) 1.19
CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer (2007) 1.17
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer (2010) 1.17
Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res (2008) 1.16
Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol (2003) 1.16